This is partly because the levels in your body fluctuate
6 An enzyme called DPP-4 circulates in the blood and cleaves the peptide almost immediately after it is released, cutting between the second and third amino acids and rendering it biologically inactive
Key Educational Points: Emphasize the experimental nature No clinical trials support this combination Highlight individual compound efficacy Both peptides show strong effects as monotherapies Discuss approved alternatives CagriSema and other studied combinations offer evidence-based options Explain regulatory status Neither compound has FDA approval for metabolic applications as of 2026 Address safety concerns Overlapping side effect profiles create legitimate risks When clients express interest in research peptides, directing them toward compounds with established safety profiles and dosing protocols serves their best interests
The researchers, led by Ravi Retnakaran, from Mount Sinai Hospital, Toronto, Canada, noted that the high cost of both GLP-1 agonists and insulin analogues is likely to be the major barrier to widespread adoption of the treatment
Bowers CY et al., Ann NY Acad Sci, 1998 865:244-249
Over Dose Consuming more amount of tablets than the prescribed dose may lead to overdose